Prolonged RV endocardial activation duration: A novel marker of arrhythmogenic right ventricular dysplasia/cardiomyopathy
Background
Parietal block, defined as intra right ventricular (RV) conduction slowing, is a major diagnostic criterion for arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C).
Objective
We evaluated the utility of total RV endocardial activation duration (EAD) measured by 3-dimensional electroanatomic mapping during sinus rhythm in the diagnosis of ARVD/C.
Methods
Twenty-five consecutive patients with frequent left bundle branch block morphology premature ventricular complexes who underwent electroanatomic mapping as a part of the evaluation for ARVD/C were included in the study. All patients were evaluated using standard protocol that included electrocardiogram (ECG), signal-averaged ECG, Holter monitoring, echocardiography, and magnetic resonance imaging. Invasive testing was performed as indicated. Total RV EAD was measured as the time interval between the onset of RV activation to the latest activated region in the RV.
Results
The mean age of the study subjects was 38 ± 11 years, and 32% were men. Fourteen subjects were diagnosed with ARVD/C using task force criteria, and the remainder had idiopathic ventricular tachycardia. Although the surface QRS durations were similar, the total RV EAD was significantly prolonged in ARVD/C compared with idiopathic VT (83.9 ± 10 ms vs. 50.8 ± 7 ms, P <.001). None of the idiopathic VT subjects had RV EAD of >65 ms. RV EAD also showed significant negative correlation with RV ejection fraction.
Conclusion
Total RV EAD obtained by 3-dimensional electroanatomic mapping is a sensitive marker of intra-RV conduction delay in ARVD/C, and a total RV EAD of >65 ms accurately differentiates ARVD/C from idiopathic VT.
Keywords: Right ventricular dysplasia, Electroanatomic mapping, Diagnosis
To access this article, please choose from the options below
Supported by the National Heart, Lung, and Blood Institute (K23HL093350 to Dr. Tandri). The Johns Hopkins ARVD Program is supported by the Bogle Foundation, St. Jude Medical Foundation, the Healing Hearts Foundation, the Campanella family, and the Wilmerding Endowments.
The authors thank the ARVD patients and families who have made this work possible.
PII: S1547-5271(09)00213-6
doi:10.1016/j.hrthm.2009.02.031
© 2009 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.
